GELS
Gelteq Ltd
$
0.880
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.9282
Open
0.8901
VWAP
0.91
Vol
19.92K
Mkt Cap
9.43M
Low
0.8751
Amount
18.06K
EV/EBITDA(TTM)
--
Total Shares
10.71M
EV
11.98M
EV/OCF(TTM)
--
P/S(TTM)
--
Gelteq Limited is an Australia-based clinical and science-based company. The Company is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The Company offers a complete end-to-end service for the development of new products and the conversion of existing products and formulations into gels. Its product suite consists of multiple products that sit within five core verticals - for pets, sports, pharmaceuticals (pharma), over-the-counter (OTC) and nutraceuticals. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. The Company also offers a versatile portfolio of pre-tested and market-ready proprietary formulations that can be white-labelled.
Show More
Valuation Metrics
The current forward P/E ratio for Gelteq Ltd (GELS.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Gelteq Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2024Q4
0.00
Total Revenue
FY2024Q4
YoY :
+23.13%
-776.72K
Operating Profit
FY2024Q4
YoY :
+19.55%
-1.13M
Net Income after Tax
FY2024Q4
YoY :
+20.00%
-0.12
EPS - Diluted
FY2024Q4
YoY :
-21.07%
-367.21K
Free Cash Flow
FY2025Q2
N/A
Gross Profit Margin - %
FY2025Q2
N/A
FCF Margin - %
FY2025Q2
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
GELS News & Events
Events Timeline
2025-10-23 (ET)
2025-10-23
09:09:32
Gelteq Launches Preclinical Trial for Drugs with Low Solubility
2025-10-09 (ET)
2025-10-09
08:15:45
Gelteq Partners with Melbourne Health for Product Development and Profit Sharing Agreement
2025-09-12 (ET)
2025-09-12
07:32:16
Gelteq Fuels Healthy Extracts' Product Launches in the U.S.
Sign Up For More Events
Sign Up For More Events
News
7.5
10-09NewsfilterGelteq Partners with Melbourne Health to Develop Innovative Compound for Reducing Bowel Polyp Growth
5.0
09-12NewsfilterGelteq Technology Supports U.S. Launch of Nutraceutical Products for Partner
2.0
09-08TipRanks3 Penny Stocks to Keep an Eye on as of September 8, 2025
Sign Up For More News
People Also Watch
ATER
Aterian Inc
0.672
USD
-3.86%
MIRA
MIRA Pharmaceuticals Inc
1.390
USD
+2.96%
COCP
Cocrystal Pharma Inc
0.901
USD
-2.07%
CCM
Concord Medical Services Holdings Ltd
3.600
USD
-9.30%
MGIH
Millennium Group International Holdings Ltd
1.300
USD
-6.47%
ATHA
Athira Pharma Inc
4.605
USD
+1.43%
OMEX
Odyssey Marine Exploration Inc
1.780
USD
+0.56%
GYRO
Gyrodyne LLC
9.390
USD
0.00%
SMSI
Smith Micro Software Inc
0.595
USD
+2.59%
FAQ
What is Gelteq Ltd (GELS) stock price today?
The current price of GELS is 0.8805 USD — it has decreased -0.68 % in the last trading day.
What is Gelteq Ltd (GELS)'s business?
What is the price predicton of GELS Stock?
What is Gelteq Ltd (GELS)'s revenue for the last quarter?
What is Gelteq Ltd (GELS)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Gelteq Ltd (GELS)'s fundamentals?
How many employees does Gelteq Ltd (GELS). have?